文献速递前列腺癌

22基因基因组分类器在高危局限性前列腺癌中的表现:临床病理模型的改良

Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-03-30

这项多中心回顾性研究纳入405例接受根治性前列腺切除或放疗联合雄激素剥夺治疗的高危前列腺癌患者,评估Decipher基因组分类器(GC)对转移的预测价值。中位随访82个月,26%患者发生转移;GC评分是转移的独立预测因子,将其加入NCCN风险分组或CAPRA模型可显著提高区分度(AUC从0.46升至0.67,从0.59升至0.71)。

要点

  • 在高危前列腺癌中,常规临床病理变量对转移的区分能力较差。
  • GC评分每增加0.1单位,转移风险独立增加33%(HR 1.33)。
  • GC高危组较低危组转移风险显著升高(HR 2.95)。

核心结论

  • 在高危前列腺癌患者中,GC评分是转移的显著独立预测因子,可改善临床病理模型的风险分层。

研究设计与样本

  • 多中心回顾性研究,纳入1995至2005年间11个中心接受根治性前列腺切除或放疗联合雄激素剥夺治疗的405例高危前列腺癌患者。

主要发现

  • 中位随访82个月,104例(26%)发生转移。
  • 单变量分析中,GC评分每增加0.1单位与转移显著相关(HR 1.34,95%CI 1.19-1.50,p<0.001),而年龄、血清PSA、活检GG和临床T分期均不显著(均p>0.05)。
  • 多变量分析中,GC评分(HR 1.33每0.1单位,95%CI 1.19-1.48,p<0.001)和GC高危(较低危HR 2.95,95%CI 1.79-4.87,p<0.001)与转移显著相关。
  • 将GC评分加入基于NCCN风险组的回归模型,AUC从0.46提高至0.67;加入CAPRA模型,AUC从0.59提高至0.71。

关键数值与推荐

  • GC评分每增加0.1单位,转移风险HR为1.33(95%CI 1.19-1.48,p<0.001)。
  • GC高危较低危的转移风险HR为2.95(95%CI 1.79-4.87,p<0.001)。
  • NCCN风险组模型加入GC后AUC从0.46升至0.67;CAPRA模型加入GC后AUC从0.59升至0.71。

临床怎么用

  • 对于高危局限性前列腺癌患者,可考虑使用GC评分辅助识别转移高风险者,以指导治疗强化或降阶梯。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer exhibits biological and clinical heterogeneity even within established clinico-pathologic risk groups. The Decipher genomic classifier (GC) is a validated method to further risk-stratify disease in patients with prostate cancer, but its performance solely within National Comprehensive Cancer Network (NCCN) high-risk disease has not been undertaken to date. METHODS: A multi-institutional retrospective study of 405 men with high-risk prostate cancer who underwent primary treatment with radical prostatectomy (RP) or radiation therapy (RT) with androgen-deprivation therapy (ADT) at 11 centers from 1995 to 2005 was performed. Cox proportional hazards models were used to determine the hazard ratios (HR) for the development of metastatic disease based on clinico-pathologic variables, risk groups, and GC score. The area under the receiver operating characteristic curve (AUC) was determined for regression models without and with the GC score. RESULTS: Over a median follow-up of 82 months, 104 patients (26%) developed metastatic disease. On univariable analysis, increasing GC score was significantly associated with metastatic disease ([HR]: 1.34 per 0.1 unit increase, 95% confidence interval [CI]: 1.19-1.50, p < 0.001), while age, serum PSA, biopsy GG, and clinical T-stage were not (all p > 0.05). On multivariable analysis, GC score (HR: 1.33 per 0.1 unit increase, 95% CI: 1.19-1.48, p < 0.001) and GC high-risk (vs low-risk, HR: 2.95, 95% CI: 1.79-4.87, p < 0.001) were significantly associated with metastasis. The addition of GC score to regression models based on NCCN risk group improved model AUC from 0.46 to 0.67, and CAPRA from 0.59 to 0.71. CONCLUSIONS: Among men with high-risk prostate cancer, conventional clinico-pathologic data had poor discrimination to risk stratify development of metastatic disease. GC score was a significant and independent predictor of metastasis and may help identify men best suited for treatment intensification/de-escalation.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Tosoian JJ, Birer SR, Jeffrey Karnes R, et al. Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. Prostate Cancer Prostatic Dis. 2020. PMID: 32231245. doi:10.1038/s41391-020-0226-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。